EP2710008A1 - Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques - Google Patents

Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques

Info

Publication number
EP2710008A1
EP2710008A1 EP12721518.4A EP12721518A EP2710008A1 EP 2710008 A1 EP2710008 A1 EP 2710008A1 EP 12721518 A EP12721518 A EP 12721518A EP 2710008 A1 EP2710008 A1 EP 2710008A1
Authority
EP
European Patent Office
Prior art keywords
acid
asenapine
crystalline
salt
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12721518.4A
Other languages
German (de)
English (en)
Inventor
Fritz Blatter
Katharina REICHENBÄCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to EP12721518.4A priority Critical patent/EP2710008A1/fr
Publication of EP2710008A1 publication Critical patent/EP2710008A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the invention relates to novel crystalline salts of Asenapine with organic di-acids and tri-acids and to methods of their preparation. Furthermore the invention relates to the use of the novel salts in pharmaceutical compositions and to the use of the novel salts as medicaments, preferably in the treatment of psychotic diseases or disorders such as schizophrenia and acute mania associated with bipolar disorder.
  • hemipamoate salt (EP569096), are described in the literature.
  • the pamoate salt is disclosed to be amorphous and the hemipamoate salt is a mixture of amorphous and crystalline phase, wherein the palmitate is described as oil.
  • the marketed form is the maleate salt, which is disclosed to exist in polymorphic forms (WO 2006/106135).
  • the known Asenapine salts have a low solubility in water. For example, Funke et. al. (Arzneim.-Forsch./Drug Res.
  • a further aspect of the invention is to provide new forms of Asenapine with a smaller tendency towards formation of polymorphic forms.
  • Polymorphism is well known in the pharmaceutical industry and active pharmaceutical ingredients (API) that exist in multiple crystalline forms (polymorphs) are generally undesired, because different polymorphs exhibit different physico-chemical properties, and in particular, if a solubility difference between two polymorphs is found this may have a direct impact on the bioavailability.
  • API active pharmaceutical ingredients
  • a premise for a sublingual dissolving tablet form is an active ingredient exhibiting good solubility in a fast dissolving matrix. It is an objective of the invention to provide pharmaceutically acceptable forms of Asenapine that may have a good solubility. It is also an object of the invention to provide Asenapine in a form that may have a good chemical and/or physical stability and/or good processability, both during its preparation and in the preparation of pharmaceutical compositions containing Asenapine. Sumnnarv of the invention
  • the crystalline salts of Asenapine with organic di- acids or tri-acids according to the invention may have beneficial properties regarding solubility and stability.
  • the novel addition salts of Asenapine with organic acids may not show polymorphism and may meet above defined criteria for solubility, chemical stability and processability and may thus avoid the known polymorph issues with the marketed maleate.
  • a crystalline polymorphically stable salt preferably in anhydrous form, of trans- 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1 H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrole
  • (Asenapine) with an organic di-acid or tri-acid wherein said salt has a solubility in water at 25°C of at least 2.0 mg/ml, preferably at least or more than 2.4 mg/ml, calculated as free base and wherein the polymorphic stability is such that essentially all, preferably at least 90 wt.%, of said salt does not change its crystal structure upon stirring in acetonitrile for 96 hours at a temperature of 20°C.
  • a crystalline salt of asenapine being preferably of any of items 1 -4, which comprises or consists of (i) crystalline Asenapine malonate form I or (ii) crystalline Asenapine citrate form I, wherein
  • crystalline Asenapine malonate form I is characterized by X-ray powder diffraction reflections (Cu Ka radiation) comprising peaks at two theta angles of about 19.5° ⁇ 0.2°, 23.7° ⁇ 0.2°, 8.5° ⁇ 0.2°, 23.1 ° ⁇ 0.2°, and 24.2° ⁇ 0.2°, and/or
  • crystalline Asenapine citrate form I is characterized by X-ray powder diffraction reflections (Cu Ka radiation) comprising peaks at two theta angles of about 15.5° ⁇ 0.2°, 15.3° ⁇ 0.2°, 12.6° ⁇ 0.2°, 23.2° ⁇ 0.2°, and 19.4°
  • a process for preparing a crystalline polymorphically stable salt according to any of items 1 -5, preferably in anhydrous form, of trans-5-chloro-2-methyl- 2,3,3a, 12b-tetrahydro-1 H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrole (Asenapine) with an organic di-acid or tri-acid comprising the steps of:
  • step (a) the organic di-acid or tri-acid can be added in pure form or as a solution in the solvent or solvent mixture used in step (a).
  • step (a) The process of item 6 or 7, wherein step (a) is carried out in the presence of seed crystals.
  • step (a) malonic acid can e.g. be added in pure form or as a solution in the solvent or solvent mixture used in step (a).
  • step (a) malonic acid can e.g. be added in pure form or as a solution in the solvent or solvent mixture used in step (a).
  • step (9) The process of any of items 6-8, wherein the crystalline polymorphically stable Asenapine salt obtained in step (b) is crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • solvent or solvent mixture comprises or consists of one or more organic solvents from the group consisting of esters, preferably acetic acid C1-C6 alkylesters, most preferably ethylacetate;
  • Ci -C 5 alcohols e.g. methanol, ethanol or propanol or mixtures thereof; mixtures of acetic acid Ci- Ce alkylesters and C1-C6 alcohols, preferable ethyl acetate and a C1-C5 alcohol, preferably ethanol; ketones, preferably acetone; combinations of acetic acid C1-C6 alkylesters; optionally in the presence of water.
  • step (a) The process of any of items 6-10, wherein step (a) is carried out at a temperature of between 15°C and the boiling temperature of the solvent or solvent mixture preferably under stirring. A temperature of between 15°C and 25°C is preferred in step (a). After stirring the reaction mixture for a time period of between 1 hour and two weeks, preferably between one day and one week, the reaction mixture can be cooled to a temperature of between 0°C and 15°C or the organic solvent/solvent mixture can be partly removed for completion of crystallization.
  • Crystalline polymorphically stable salt in particular in anhydrous form, of Asenapine with an organic di-acid or tri-acid according to any of items 1 -5 or obtained or obtainable according to any of items 6-1 1 as medicament, preferably for the treatment of psychotic diseases or disorders, wherein the salt preferably is or comprises crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • composition comprising one or more crystalline polymorphically stable salts, in particular in anhydrous form, of Asenapine with an organic di-acid or tri-acid according to any of items 1 -5 or obtainable or obtained according to the process of any of items 6-1 1 .
  • composition comprising one or more crystalline polymorphically stable salts, in particular in anhydrous form, of Asenapine with an organic di-acid or tri-acid according to any of items 1 -5 or obtainable or obtained according to the process of any of items 6-1 1 .
  • composition or dosage form of items 13 or 14, wherein at least 90 wt.%, further preferred at least 95 wt.%, even further preferred at least 98 wt.%, of Asenapine being present in said composition or dosage form is a crystalline polymorphically stable salt of Asenapine with an organic di-acid or tri- acid as described herein, preferably crystalline Asenapine malonate form I, and/or crystalline Asenapine citrate form I.
  • Asenapine maleate represents a salt of Asenapine with a di-acid
  • Asenapine salt according to the invention does not represent Asenapine.
  • Trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1 H-dibenz[2,3:6,7] oxepino[4,5- c]pyrrole (Asenapine/Asenapine free base) has a structure according to Formula I
  • the invention refers to crystalline salts of Asenapine.
  • the invention refers to a crystalline polymorphically stable salt, preferably in anhydrous form, of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1 H-dibenz[2,3:6,7] oxepino[4,5- c]pyrrole (Asenapine) with an organic di-acid or tri-acid, wherein said salt has a solubility in water at 25°C of more than 2.4 mg/ml, calculated as free base and wherein the polymorphic stability is such that at least 90 wt.% of said salt does not change its crystal structure or maintains its crystal structure upon stirring in acetonitrile for 96 hours at a temperature of 20°C.
  • the X-ray powder diffraction reflection pattern does not change during the testing, i.e. no additional peaks (of a new polymorphic crystal form of said salt) can be identified, when comparing a sample of the salt prior to the polymorphic stability testing with a sample that has been subjected to stability testing as described in detail below.
  • the polymorphic stability test as described above is carried out by using acetonitrile in admixture with water (90:10 by volume)
  • the polymorphic stability testing method as described herein allows for efficient testing and identifying polymorphic salts according to the invention.
  • the polymorphic stability of the salt according to the invention is preferably measured according to the method described below.
  • the Asenapine salts according to the invention have a solubility in water of at least 2.4 mg/ml, but may also have a solubility of at least 3.9 mg/ml.
  • a typical maximum solubility of the salts according to the invention can e.g. be 30 mg/ml, 20 mg/ml or 15 mg/ml .
  • the solubility of the salts is determined as described below.
  • Organic di-acid and tri-acid according to the invention can be any organic acids having two or three acid functions, wherein the acid functions preferably are carboxylic acid functions.
  • the organic di-acids or tri-acids may have 3 to 20, further preferred 3 to 14, preferably 3 to 6 carbon atoms in total. They may represent saturated or unsaturated, preferably saturated, carboxylic di-acids or tri- acids.
  • the organic acids according to the invention can optionally be substituted, e.g. with heteroatoms, however, the may only comprise the acid functions and optionally additional hydroxy or carboxy
  • the organic di-acid according to the invention is malonic acid (CsH O 4 ) or citric acid (C6H 8 O 7 ).
  • said salt is an anhydrous salt of Asenapine with malonic acid or citric acid.
  • anhydrous form as used in the context of the invention means that the salt contains less than a stoichiometric amount of water preferably less 1 wt. % of water.
  • the molar ratio of Asenapine to the organic di-acid or tri-acid in said salt is between 1 :1 .3 to 1 .3:1 , preferably about 1 :1 .
  • the ratio of Asenapine to the organic di-acid or tri-acid can be determined by H-NMR spectroscopy and/or elementary analysis.
  • crystal structures of novel 1 :1 salts of Asenapine with an organic di-acid or tri-acid of Formula II H 2 O molecules optionally being present in the salt are not shown:
  • R is chosen so that R-COO " represents an organic di-acid or tri-acid, preferably malonate or citrate, wherein one acid function is deprotonated.
  • Water can be present in the salts according to the invention in an amount of 0 to 4 molecules per Asenapine molecule, or 0 to 2 molecules per Asenapine molecule, preferably the amount of water is less than 1 molecule per Asenapine molecule (i.e. less than a stoichiometric amount of water). In one embodiment, the water uptake of the salt according to the invention is less than 3 wt. %, preferably less than 2 wt. %, preferably less than 1 wt. %, preferably less than 0.5 wt.
  • Crystalline Asenapine malonate form I of the invention is characterized by X-ray powder diffraction reflections comprising peaks at two theta angles of about 8.5° ⁇ 0.2°, 19.5° ⁇ 0.2°, 23.1 ° ⁇ 0.2°, 23.7° ⁇ 0.2°and 24.2° ⁇ 0.2°.
  • Crystalline Asenapine malonate form I is preferably characterized by a PXRD pattern substantially in accordance with Figure 1 , in particular the PXRD pattern comprises the peaks as given in Table 3.
  • the Asenapine malonate may contain small amounts of water. Dynamic vapor experiments showed that the water uptake even up to 95% rel . humidity is
  • the crystalline Asenapine malonate may be completely non-hygroscopic.
  • the aqueous solubility of the malonate of the invention was determined to be
  • aqueous solubility was determined after 40 hours of suspension equilibration at 25°C. Thereafter, the suspensions were filtered and the concentration in the liquid phase was determined by HPLC.
  • a crystalline salt of Asenapine in form of a citrate is provided.
  • Crystalline Asenapine citrate form I of the invention is characterized by X-ray powder diffraction reflections comprising peaks at two theta angles of about 12.6° ⁇ 0.2°, 15.3° ⁇ 0.2°, 15.5° ⁇ 0.2°, 19.4° ⁇ 0.2° and 23.2° ⁇ 0.2°.
  • the crystalline citrate of the invention can be further characterized by a PXRD pattern substantially in
  • the PXRD pattern comprises the peaks as given in Table 1 .
  • the Asenapine salts described herein are preferably characterized by their PXRD pattern, i.e. the peaks as given in the respective peak tables.
  • the hygroscopic nature of the citrate salt was investigated by dynamic vapor sorption.
  • the citrate may absorb about 1 .5% of water and most of the water uptake occurs above 80% relative humidity. Therefore the Asenapine citrate of the invention is not or only very slightly hygroscopic.
  • the aqueous solubility of the citrate of the invention was determined to be
  • the crystalline salt comprises or consists of (i) crystalline Asenapine malonate form I or (ii) crystalline Asenapine citrate form I, wherein (i) crystalline Asenapine malonate form I is characterized by X-ray powder diffraction reflections comprising peaks at two theta angles of about 19.5° ⁇ 0.2°, 23.7° ⁇ 0.2°, 8.5° ⁇ 0.2°, 23.1 ° ⁇ 0.2°, and 24.2° ⁇ 0.2°, and
  • crystalline Asenapine citrate form I is characterized by X-ray powder diffraction reflections comprising peaks at two theta angles of about 15.5° ⁇ 0.2°, 15.3° ⁇ 0.2°, 12.6° ⁇ 0.2°, 23.2° ⁇ 0.2°, and 19.4° ⁇ 0.2°.
  • Crystalline Asenapine malonate form I and crystalline Asenapine citrate form I have a solubility in water at 25°C of more than 2.0 mg/ml, calculated as free base, and a polymorphic stability of such that more than 90 wt. % of said salt does not change its crystal structure upon stirring in acetonitrile or a mixture of acetonitrile and water for 96 hours at a temperature of 20°C.
  • the invention refers to crystalline Asenapine malonate form I and crystalline Asenapine citrate form I.
  • the crystalline salt comprises at least 80 wt. %, further preferred at least 90 wt. %, even further preferred at least 95 wt.
  • polymorphic form of Asenapine with an organic di-acid or tri- acid preferably, the polymorph is crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • the invention also refers to a process for preparing a crystalline polymorphically stable salt, preferably in anhydrous form, of trans-5-chloro-2-methyl-2,3,3a,12b- tetrahydro-1 H-dibenz[2,3:6,7] oxepino[4,5-c]pyrrole (Asenapine) with an organic di-acid or tri-acid comprising the steps of:
  • the organic di-acid or tri-acid is a carboxylic di-acid or carboxylic tri- acid, preferably an unsaturated C3-Ci 4 carboxylic di-acid or tri-acid, further preferred malonic acid or citric acid.
  • Preferred di-acids and tri-acids are also described above.
  • the amount of organic di-acid or tri-acid is not critical and may e.g. be 0.8 to 2 moles of organic di-acid or tri-acid per mole of Asenapine. However, a molar excess of organic di-acid or tri-acid to Asenapine base is preferred for maximizing the yield. For example an amount of at least 2 or of at least 5 moles, also of at least 10 moles %, to about 50 moles % of the organic di-acid or tri-acid can be used.
  • step (a) is carried out at a temperature of between 15°C and the boiling temperature of the organic solvent or organic solvent mixture optionally containing water, preferably under stirring (e.g. 600 rpm), for a period of time sufficient to induce crystallization, preferably of between 1 hour and two weeks, preferably between one day and one week.
  • step (a) is carried out in the presence of seed crystals.
  • seed crystals refers to that type of crystals that help produce the desired crystal form of Asenapine salt. For example, if it is desired to produce crystalline Asenapine malonate form I or crystalline
  • the seed crystals to be used to enhance the crystallization process can e.g. be crystals of crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • Asenapine salts in anhydrous form it is preferred that water - if present in the reaction mixture - is removed e.g. by distillation.
  • Combining Asenapine free base with an organic di-acid or tri-acid in an organic solvent or organic solvent mixture and obtaining said crystalline polymorphically stable Asenapine salt can be carried out by methods known in the art.
  • the organic di-acid or tri-acid can be added to the Asenapine free base in the organic solvent or solvent mixture in pure form or can be dissolved in an organic solvent or water as defined herein.
  • step (a) Asenapine free base is dissolved in the organic solvent or organic solvent mixture and then the organic di- acid or tri-acid is added, preferably under stirring.
  • a solution of Asenapine free base is added to a solution of organic di-acid or tri-acid.
  • the solvent system used for dissolving Asenapine free base is the same as used for dissolving the organic di-acid or tri-acid.
  • the organic di-acid or tri-acid is dissolved in water.
  • Crystallization may be completed by addition of an antisolvent.
  • crystallization may be enhanced by cooling the reaction mixture obtained in step (a) or by partly removing organic solvent from the reaction mixture either during or after step (a).
  • obtaining said crystalline Asenapine salt in step (b) comprises isolation of said salt by filtration, washing the obtained salt and drying said salt.
  • the crystalline polymorphically stable Asenapine salt obtained in step (b) is crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • the solvent or solvent mixture that is used in the process in step (a) preferably comprises or consists of one or more organic solvents from the group consisting of esters, preferably acetic acid C1-C6 alkylesters, most preferably ethylacetate;
  • Ci -C 5 alcohols e.g. methanol, ethanol or propanol or mixtures thereof; mixtures of acetic acid Ci- Ce alkylesters and C1-C6 alcohols, preferable ethyl acetate and a C1-C5 alcohol, preferably ethanol; ketones, preferably acetone; combinations of acetic acid C1-C6 alkylesters; optionally in the presence of water
  • a suitable amount of solvent or solvent mixture can easily be chosen by a person skilled in the art.
  • the amount of solvent or solvent mixture is chosen in order to at least dissolve Asenapine free base
  • the crystalline Asenapine malonate form I of the invention may be prepared by a) combining Asenapine free base with malonic acid in a suitable solvent, and b) crystallizing Asenapine malonate optionally in the presence of seeds.
  • Preferred solvents include but are not limited to esters, preferably acetic acid
  • Ci-C 4 alkylesters most preferably ethylacetate, or mixtures thereof; alcohols, preferable Ci -C 4 alcohols, e.g. methanol, ethanol or propanol or mixtures thereof; or mixtures of acetic acid Ci- C 4 alkylesters and Ci-C 4 alcohols.
  • the malonic acid may be used as such or as solution in above mentioned solvents or solvent mixtures.
  • the amount of malonic acid is not critical, e.g. 0.8 to 2 moles of malonic acid per mole of Asenapine may be used.
  • the crystalline malonate of the invention is polymorphically stable, e.g. by stirring a suspension of the malonate in water at 25°C no polymorph conversion was observed. No polymorph conversion was also observed stirring a suspension of the crystalline Asenapine malonate of the invention for 4 days at ambient temperature.
  • the crystalline citrate of the invention may be prepared by a) combining Asenapine free base with citric acid in a suitable solvent, and b) crystallizing Asenapine citrate optionally in the presence of seeds.
  • Preferred solvents include but are not limited to ketones, more preferably acetone; acetic acid C1-C6 alkylesters, preferably ethyl acetate; combinations of acetic acid C1-C6 alkylesters or combinations of acetic acid C1-C6 alkylesters with alcohols and/or ketones, preferable ethyl acetate and a C1-C5 alcohol, preferably ethanol; optionally in the presence of water.
  • the amount of citric acid is not critical and may e.g. be 0.8 to 2 moles per mole of Asenapine. However, a molar excess of citric acid to Asenapine base is preferred for maximizing the yield e.g. an excess of about 10 molar % to about 50 molar %.
  • the temperature in the crystallization step is not critical, e.g. temperatures of about ambient temperature up to the boiling point of the solvent may be used. Conveniently, the crystallization is performed at ambient temperature and the suspension may then be cooled to complete the crystallization.
  • Citric acid anhydrous citric acid or the monohydrate are suitable sources for the preparation of the crystalline Asenapine citrate salt.
  • the citric acid may be used as such or as a solution, preferably as solution in water, e.g. at about 20% to about 60% (w/w) solution in water.
  • the ratio of organic solvent to water in the crystallization step is not critical, however to maximize yield a ratio of water to organic solvent(s), preferably acetone, in the crystallization step is from about 7:3 to 9:1 (v/v).
  • the Asenapine citrate of the invention is polymorphically stable, e.g. it does not change its polymorphic form in a suspension in water at 25° C respectively equilibration in acetonitrile for 5 days, thus eliminating the problem formulating the known maleate according to WO 95/23600 and WO 2006/16135.
  • step (a) is carried out at a temperature of between 15°C and the boiling temperature of the solvent or solvent mixture preferably under stirring (e.g. 600 rpm), for a period of time sufficient to induce crystallization, preferably of between 1 hour and two weeks, preferably between one day and one week.
  • the invention also refers to crystalline salts of Asenapine obtainable or obtained according to the process as described above.
  • the invention also refers to a crystalline polymorphically stable salt, in particular in anhydrous form, of Asenapine with an organic di-acid or tri-acid according to the invention as medicament, preferably for the treatment of psychotic diseases or disorders, wherein the salt preferably is or comprises crystalline Asenapine malonate form I or crystalline Asenapine citrate form I.
  • Other preferred salts are described above.
  • the invention also refers to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more crystalline polymorphically stable salts, in particular in anhydrous form, of
  • Asenapine with an organic di-acid or tri-acid according to the invention.
  • Preferred salts are described above.
  • the invention also refers to a pharmaceutical dosage form comprising one or more crystalline polymorphically stable salts, in particular in anhydrous form, of
  • Asenapine with an organic di-acid or tri-acid according to the invention.
  • said pharmaceutical formulation or dosage form comprises one or more salts of the invention and at least one pharmaceutically acceptable carrier or diluent.
  • At least 80 wt.%, further preferred at least 90 wt.%, also preferred at least 95 wt. %, and also preferred at least 98 wt.%, of Asenapine being present in said composition or dosage form is a crystalline polymorphically stable salt of Asenapine with an organic di-acid or tri-acid, preferably crystalline Asenapine malonate form I, and/or crystalline Asenapine citrate form I.
  • the crystalline malonate of the invention and the crystalline citrate of the invention may be formulated as disclosed for example in Example 16 of WO 2006/106135 by mixing the novel crystalline salt into a gelatin/mannitol/water mixture and freeze drying, preferably after dosing into pre-formed pockets.
  • Other ways of formulating Asenapine salts into pharmaceutical compositions or dosage forms are known in the art.
  • Powder X-ray diffraction was carried out with a Bruker D8 Advance powder X-ray diffractometer using Cui a radiation in reflection (Bragg-Brenatno) geometry. 2 ⁇ values usually are accurate within an error of ⁇ 0.1 -0.2°.
  • the samples were generally prepared without any special treatment other than the application of slight pressure to get a flat surface.
  • Two different Silicon single crystal sample holder types were used: a) a standard holder with 0.1 mm in depth, and b) a 0.5 mm depth sample holder with 12 mm cavity diameter. Normally samples were measured uncovered.
  • the tube voltage was 40 kV and current was 40 mA.
  • the PXRD diffractometer is equipped with a LynxEye detector. A variable
  • FT-Raman spectra were recorded on a Bruker RFS 100 FT-Raman system with a near infrared Nd:YAG laser operating at 1064 nm and a liquid nitrogen-cooled germanium detector. 64 scans with a resolution of 2 cm "1 were accumulated in the range from 3500 to 50 cm "1 . In general, 100 mW laser power was used.
  • Thermogravimetric measurements were carried out with a Netzsch Thermo- Microbalance TG 209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample pans with a pinhole, N 2 atmosphere, heating rate 10 K/min).
  • the water uptake of the salts according to the invention is determined by dynamic vapor sorption by exposing the salt to an atmosphere of 95% humidity. Determining solubility of Asenapine salts:
  • polymorphic stability is such that said the salts according to the invention do not change their crystal structure, i.e. maintain their crystal structure upon stirring in acetonitrile (or a mixture of acetonitrile and water as defined above) for 96 hours at a temperature of 20°C.
  • the stability test is carried out by stirring the sample salt at 600 rpm in an amount of approximately 0,1 g/ml acetonitrile and optionally water as defined above. After 96 hours of stirring, the salt is removed by filtration and is dried and then subjected to X-ray powder diffraction analysis.
  • Asenapine free base ( ⁇ 0.5 mmol) was dissolved in a mixture 8.0 ml of a 0.05 M stock solution of citric acid (Fluka #24788) in ethanol and 2.0 ml 0.05 M stock solution of citric acid in ethyl acetate (-0.5 mmol citric acid).
  • a part of the solvent mixture was evaporated under a weak flow of nitrogen about 20 ml/min and after evaporation of about 8 ml of the solvent mixture 2.0 ml ethyl acetate was added and a suspension was obtained within a few hours.
  • H-NMR spectroscopy showed an Asenapine citrate salt with an approximate 1 :1 ratio of Asenapine to citric acid.
  • Light microscopy revealed that the salt was crystalline and it showed a PXRD pattern as depicted in Figure 2 with the most important peaks as provided in Table 1 .
  • TG-FTIR did not reveal any significant mass loss upon heating to 180°C at a rate of 10 K/min.
  • the Raman spectrum of the crystalline citrate comprises peaks at wavenumbers of about 1602 cm “1 , 1581 cm “1 , 1048cm “1 , 71 1 cm “1 and 346 cm “1 .
  • Table 1 PXRD peak table for crystalline Asenapine citrate form I
  • Example 4 Stability of the crystalline form of crystalline Asenapine citrate form I with respect to polymorph conversion 77 mg crystalline Asenapine citrate form I according to Example 2 was suspended in 2.0 ml water and the glass vial was placed on a standard laboratory shaker (Eppendorf) at 25°C and 600 rpm for two days. After two days of equilibration the suspension was filtered and the recovered solid investigated by PXRD which confirmed the presence of the same crystalline form as in example 2; i.e., no phase transformation was observed. The aqueous solubility was determined by measuring the concentration of asp in the filtered solution by HPLC.
  • Example 5 Stability of crystalline Asenapine citrate form I with respect to polymorph conversion
  • Example 6 Preparation of crystalline Asenapine malonate form I seed crystals 100 mg asp free base was dissolved in 3.0 ml ethyl acetate and to this solution 165 ⁇ of a 2.0 M stock solution of malonic acid (Fluka # 63290) in methanol was added. The solvents from the clear solution were evaporated under nitrogen and to the oily residue 1 .0 ml ethyl acetate was added. After a few hours stirring at room temperature a suspension was obtained which was filtered. About 104 mg of solid product was obtained after short drying in air at room temperature.
  • the produced salt was characterized and by FT- Raman spectroscopy and by powder X-ray diffraction which indicated that the same crystalline form as in example 6 was obtained.
  • Light microscopy revealed very small crystalline particles and TG-FTIR showed only a small mass loss of about 1 .8% upon heating to 150°C at a rate of 10 K/min.
  • the Raman spectrum of the crystalline malonate comprises peaks at wave- numbers of about 1065 cm “1 , 1584 cm “1 , 121 5 cm “1 , 843 cm “1 , 71 1 cm “1 and
  • Example 10 Stability of the crystalline form of crystalline Asenapine malonate form I with respect to polymorph conversion.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux sels cristallins d'asénapine (I) contenant des diacides et triacides organiques et leurs procédés de préparation. L'invention concerne en outre l'utilisation de ces nouveaux sels dans des compositions pharmaceutiques et l'utilisation de ces nouveaux sels comme médicaments, de préférence dans le traitement de maladies ou de troubles psychotiques tels que la schizophrénie et la manie aiguë associée à un trouble bipolaire.
EP12721518.4A 2011-05-17 2012-05-15 Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques Withdrawn EP2710008A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12721518.4A EP2710008A1 (fr) 2011-05-17 2012-05-15 Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11166311A EP2524919A1 (fr) 2011-05-17 2011-05-17 Nouveaux sels cristallins d'asénapine avec des di-acides et des tri-acides cristallins
PCT/EP2012/058963 WO2012156383A1 (fr) 2011-05-17 2012-05-15 Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques
EP12721518.4A EP2710008A1 (fr) 2011-05-17 2012-05-15 Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques

Publications (1)

Publication Number Publication Date
EP2710008A1 true EP2710008A1 (fr) 2014-03-26

Family

ID=44246128

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11166311A Withdrawn EP2524919A1 (fr) 2011-05-17 2011-05-17 Nouveaux sels cristallins d'asénapine avec des di-acides et des tri-acides cristallins
EP12721518.4A Withdrawn EP2710008A1 (fr) 2011-05-17 2012-05-15 Nouveaux sels cristallins d'asénapine contenant des diacides et triacides organiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11166311A Withdrawn EP2524919A1 (fr) 2011-05-17 2011-05-17 Nouveaux sels cristallins d'asénapine avec des di-acides et des tri-acides cristallins

Country Status (3)

Country Link
US (1) US9169262B2 (fr)
EP (2) EP2524919A1 (fr)
WO (1) WO2012156383A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2019002204A1 (fr) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
EP0569096A1 (fr) 1992-05-08 1993-11-10 Akzo Nobel N.V. Préparation de dépôt
BR9506924A (pt) 1994-03-02 1997-09-30 Akzo Nobel Nv Composição farmacêutica sublingual ou bucal e utilização do trans-5-cloro-2-metil-2,3,3a, 12b-tetraidro-1h-dibenz(2,3:6,7) oxepino(4,5-c)pirrol
PL337027A1 (en) 1997-05-26 2000-07-31 Akzo Nobel Nv Salts of aromatic sulphonic acids
GB0417977D0 (en) 2004-08-12 2004-09-15 Seabait Ltd "Enhanced aquaculture feeds"
CA2603509C (fr) 2005-04-07 2013-12-03 N.V. Organon Forme cristalline du maleate d'asenapine
TW200817414A (en) * 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
WO2008148515A1 (fr) 2007-06-05 2008-12-11 Synthon B.V. Administration intranasale d'asénapine et compositions à cet usage
WO2009135091A1 (fr) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Utilisation d’asénapine et composés associés pour le traitement de maladies ou de conditions neurales ou non

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2012156383A1 *

Also Published As

Publication number Publication date
US20140128444A1 (en) 2014-05-08
WO2012156383A1 (fr) 2012-11-22
US9169262B2 (en) 2015-10-27
EP2524919A1 (fr) 2012-11-21

Similar Documents

Publication Publication Date Title
RU2489435C2 (ru) Полезные фармацевтические соли 7-[(3r,4r) -3-гидрокси-4- гидроксиметил- пирролидин -1- илметил ]- 3,5- дигидро-пирроло [ 3,2-d] пиримидин-4-она
US9567317B2 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
JP2015525227A (ja) ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
US9169262B2 (en) Crystalline salts of Asenapine with organic di-acids and tri-acids
EP2601175A1 (fr) Nouveau composé cristallin comprenant de la saxagliptine et de l'acide phosphorique
US20140163083A1 (en) Novel crystalline salts of asenapine
TWI519535B (zh) 安定的ｓｎｓ-５９５組合物及其製備方法
EP2710009B1 (fr) Nouvelles formes de sels de chlorhydrate d'asénapine cristallins
KR20080090661A (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
JP2005298424A (ja) エパルレスタット結晶の製造方法
JP6193762B2 (ja) １−｛（２Ｓ）−２−アミノ−４−［２，４−ビス（トリフルオロメチル）−５，８−ジヒドロピリド［３，４−ｄ］ピリミジン−７（６Ｈ）−イ
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
JP2021510149A (ja) アカラブルチニブの新規結晶形及びその製造方法並びに用途
ES2326493T3 (es) Maleato de 3-(2-(dimetilamino)metil-(ciclohex-1-il))fenol y sus formas cristalinas.
US20160122274A1 (en) Salts of Sitagliptin, Process from the Preparation and Pharmaceutical Composition Therefore
TW202102510A (zh) 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物
CN103819461B (zh) N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
US20230286998A1 (en) Succinate salts of octahydrothienoquinoline compound and crystals thereof
CN107868059B (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
KR20060103997A (ko) 신규한 결정형 시부트라민 유기산염과 그의 제조방법
KR102271944B1 (ko) 시스테인 프로테아제 억제제로서 유용한 n-[1-6-(에티닐-3-옥소-헥사하이드로-푸로[3,2-b]피롤-4-카르보닐)-3-메틸-부틸]-4-[5-플루오로-2-(4-메틸-피페라지닐)티아졸-4-일]-벤즈아미드의 염의 2형 결정질 다형체
JP2021098689A (ja) 超高純度トレプロスチニルを調製するための効率的な結晶化プロセス及びそれから調製された結晶
WO2014147641A2 (fr) Sel de phosphate de sitagliptine et de ptérostilbène, son procédé de préparation et composition pharmaceutique en contenant
JP2022510928A (ja) フロピリミジン化合物の塩および結晶形ならびにその医薬用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170624